Free Writing Prospectus - Filing Under Securities Act Rules 163/433 (fwp)
December 09 2020 - 06:02AM
Edgar (US Regulatory)
Issuer General Use Free Writing Prospectus
Filed pursuant to Rule 433
Registration Statement No.: 333-226558
Issuer Free Writing Prospectus dated December 8, 2020
Relating to Preliminary Prospectus Supplement dated December 8,
2020
TERM SHEET
CEL-SCI CORPORATION
Public Offering of Common Stock
This document does not provide full disclosure of all material
facts relating to the securities offered. Investors should read the
accompanying prospectus, any amendment and any applicable
prospectus supplement for disclosure of those facts, especially
risk factors relating to the securities offered, before making an
investment decision.
A preliminary prospectus supplement to the accompanying prospectus
dated December 8, 2020 has been filed with the Securities and
Exchange Commission (SEC) in the United States and contains
important information relating to the securities described in this
term sheet. The issuer has filed a registration statement
(including the accompanying prospectus) with the SEC for the
offering to which this communication relates. Before you invest,
you should read the prospectus, as supplemented by the preliminary
prospectus supplement filed with the SEC, in that registration
statement and other documents the issuer has and will file with the
SEC for more complete information about the issuer and this
offering. You may get these documents for free by visiting EDGAR on
the SEC website at www.sec.gov. Alternatively, the issuer, any
underwriter or any dealer participating in the offering will
arrange to send you the prospectus, as supplemented, if you request
it, from Kingswood Capital Markets, Attention: Syndicate Desk, 17
Battery Place, Suite 625, New York, NY 10004, by email at
syndicate@kingswoodcm.com, or by telephone at (212)
404-7002.
Issuer:
|
|
CEL-SCI
Corporation (the “Company”)
|
|
|
|
Number of Firm Shares:
|
|
1,000,000
shares of common stock of the Company (each, a “Share”).
|
|
|
|
Public price per Share:
|
|
$14.65
|
Option to purchase additional Shares:
|
|
The
Underwriters (as defined below) will have an option, exercisable,
in whole or in part, in the sole discretion of the Underwriters, at
any time prior to the day that is the 30th day following the date
of the Underwriting Agreement, to purchase up to an additional
150,000 Shares on the same terms and conditions as set forth
herein.
|
|
|
|
Form of Underwriting:
|
|
Firm
commitment underwriting public offering by way of a prospectus
supplement to the Company’s effective “shelf”
registration statement (File No. 333-226558) (the
“Offering”),
subject to a mutually acceptable underwriting agreement containing
the customary material adverse effect clauses.
|
Underwriter:
|
|
Kingswood
Capital Markets, division of Benchmark Investments, Inc. and Aegis
Capital Corp. is acting as the joint book-running managers for the
Offering (the “Underwriters”).
|
|
|
|
Jurisdictions:
|
|
No
action is being taken in any jurisdiction outside the United States
to permit a public offering of the Shares. None of the Shares in
this Offering will be offered or sold, directly or indirectly, nor
will any offering material or advertisements in connection with the
offer and sales of any of the Shares be distributed or published in
any jurisdiction, except under circumstances that will result in
compliance with the applicable rules and regulations of that
jurisdiction.
|
|
|
|
Underwriter’s Fees:
|
|
The
Company will pay the Underwriter a commission equal to 7.0% of the
gross proceeds of the Offering. The Company will reimburse the
Underwriter for certain expenses including $65,000 for actual fees
and expenses including legal fees, or $25,000 if the offering is
not consummated.
|
|
|
|
Use of Proceeds:
|
|
The net
proceeds of the Offering will be used to fund the continued
development of Multikine and LEAPS, for the expansion of the
Company’s manufacturing facility and for other general
corporate purposes.
|
|
|
|
Listing:
|
|
Our
common stock is listed on the NYSE American under the symbol
“CVM.”
|
|
|
|
Closing Date:
|
|
On or
about December 11, 2020 or such other date as the Company and the
Underwriter mutually agree.
|
Cel Sci (AMEX:CVM)
Historical Stock Chart
From Feb 2024 to Mar 2024
Cel Sci (AMEX:CVM)
Historical Stock Chart
From Mar 2023 to Mar 2024